ABC UK is delighted to announce the successful grant recipients for the 2024 round of ‘Improving Outcomes for Patients Programme' grants.

This study aims to improve hospital management of patients with haematuria, primarily caused by bladder cancer. It will evaluate outcomes such as hospital stay duration, operation timing, and readmissions. The findings will help create UK best practice guidelines, aiming to standardise care and improve outcomes for this high-risk patient group.

Find out more... 

---

Selecting Hypoxic Tumours for Treatment Modification.

Aiming to measure oxygen levels in bladder cancer using genetic analysis of biopsy tissue to optimise treatment. It will establish a process for generating real-time hypoxia signature scores, guiding targeted treatments and potentially improving survival rates for bladder cancer patients.

Find out more...

---

Chemosensitivity of Bladder Cancer Cells with ZFP36L1 Mutations.

This project targets a novel vulnerability in bladder cancer found in over 8% of cases. By testing the chemosensitivity of bladder cancers with ZFP36L1 mutations, it aims to identify effective existing drugs. The results could pave the way for new targeted therapies for this significant patient subgroup.

Find out more...

Gathering patient input on essential clinical trial outcomes for a Core Outcome Set (COS) to ensure standardised outcome reporting, aiding comparison and improving informed decision-making for patients. This approach addresses current inconsistencies in trial results, enhancing the development of evidence-based clinical guidelines and patient care.

Find out more... 

This project aims to identify proteins regulating CDK1 in invasive bladder cancer cells to discover new drug targets. Understanding these mechanisms could lead to novel therapies and improve outcomes for patients with muscle-invasive bladder cancer, addressing a significant gap in current treatment options.

Find out more... 

Read more about previous grant-awarded projects, other bladder cancer research or clinical trials.